

## Active substances set

**Search phrase:** Liver cancer

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

### Liver cancer

#### Regorafenib

Regorafenib jest wskazany w monoterapii do leczenia dorosłych pacjentów z rakiem wątrobowokomórkowym (ang. hepatocellular carcinoma, HCC), którzy wcześniej byli leczeni sorafenibem.

 **NO REIMBURSEMENT**  
 **ESMO**

#### Lenvatinib

Lenvatinib w monoterapii jest wskazany w leczeniu dorosłych pacjentów z zaawansowanym lub nieoperacyjnym rakiem wątrobowokomórkowym, którzy nie byli poddani wcześniej leczeniu ogólnemu.

 **NO REIMBURSEMENT**  
 **ESMO**

#### Ramucirumab

Ramucirumab monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of  $\geq 400$  ng/ml and who have been previously treated with sorafenib.

 **NO REIMBURSEMENT**  
 **ESMO**

#### Pembrolizumab

Pembrolizumab, in combination with gemcitabine and cisplatin, is indicated for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma (BTC) in adults. Pembrolizumab as monotherapy is indicated for the treatment of the following microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) tumours in adults with unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.

 **NO REIMBURSEMENT**  
 **ESMO**

## Cabozantinib

Cabozantinib is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.

 **REIMBURSEMENT  
WITH RESTRICTIONS**

 **ESMO**

---

## Atezolizumab

Atezolizumab, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

 **FULL  
REIMBURSEMENT**

 **ESMO**

---

## Durvalumab

Biliary Tract Cancer (BTC) Durvalumab in combination with gemcitabine and cisplatin is indicated for the first-line treatment of adults with unresectable or metastatic biliary tract cancer (BTC). Hepatocellular Carcinoma (HCC) Durvalumab as monotherapy is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC). Durvalumab in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).

 **FULL  
REIMBURSEMENT**

 **ESMO**